Bassel Nazha, MD, MPH

• Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

  • Phase

    II
  • Conditions

    Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Sporadic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
  • Location

    Emory University Hospital Midtown, Emory Saint Joseph's Hospital, Winship Cancer Institute

• Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

  • Phase

    II
  • Conditions

    Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Neoplasm, Malignant Ureter Neoplasm, Malignant Urethral Neoplasm, Metastatic Bladder Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Unresectable Bladder Carcinoma, Urachal Adenocarcinoma, Bladder Adenocarcinoma
  • Location

    Emory University Hospital Midtown, Emory Saint Joseph's Hospital, Winship Cancer Institute

• Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

  • Phase

    II/III
  • Conditions

    Renal Pelvis and Ureter Urothelial Carcinoma
  • Location

    Emory University Hospital Midtown, Winship Cancer Institute

• Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer

  • Phase

    II
  • Conditions

    Prostate Cancer Metastatic, Neuroendocrine Tumors
  • Location

    Emory University Hospital Midtown, Winship Cancer Institute, Grady Health System

• Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

  • Phase

    II
  • Conditions

    Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8
  • Location

    Emory University Hospital Midtown, Winship Cancer Institute

Neoadjuvant platinum-based chemotherapy and lymphadenectomy for penile cancer: an international, multi-institutional, real-world study.

Journal of the National Cancer Institute

Linear Muscle Segmentation for Metastatic Renal Cell Carcinoma: Changes in Clinic-Friendly Estimation Predict Survival Following Cytoreductive Nephrectomy.

Clinical genitourinary cancer

Billing for Electronic Patient-Physician Communications: An Ethical Analysis.

JCO oncology practice

Adrenocortical Carcinomas: Molecular Pathogenesis, Treatment Options, and Emerging Immunotherapy and Targeted Therapy Approaches.

The oncologist

Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers.

Cancer

Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors.

The oncologist

The Genomic Landscape of Urothelial Carcinoma with High and Low ERBB2 Expression.

Cancers

Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors.

Journal of the National Cancer Institute

Combined Programmed Death-Ligand 1 and MET Inhibition: Has Papillary Renal Cell Carcinoma MET Its Match?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.

The oncologist

Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience.

Journal of immunotherapy and precision oncology

Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER-Medicare Database Analysis.

Cancers

High throughput, label-free isolation of circulating tumor cell clusters in meshed microwells.

Nature communications

Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials.

Cancers

Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma.

The oncologist

Baseline basophil and basophil-to-lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancer.

Urologic oncology

Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients.

Clinical genitourinary cancer

Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy.

Frontiers in endocrinology

Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah's witness: A case report.

Frontiers in oncology

Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors.

The oncologist

Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options.

The oncologist

Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.

The oncologist

Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.

Journal for immunotherapy of cancer

Circulating interleukin 6, androgen deprivation therapy, and fatigue in prostate cancer: Is inflammation the link?

Cancer

Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors.

Frontiers in oncology

Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade.

Frontiers in oncology

Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer.

Cancer

Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study.

Journal for immunotherapy of cancer

05/22/2024

No bad experiences.

05/10/2024

Dr Bassel Nazha and Nurse Jerusalem were the best and warmest healthcare pro's i've met. Cheers to them.

04/17/2024

Beautiful building

04/17/2024

Dr. Nazha was very attentive and informative regarding my medical needs.

03/08/2024

Dr Nazha is probably one of the most capable doctors that I've ever been to and as far as I'm concerned he will be my Doctor concerning relative issues as long as I live again, thank you for asking

03/08/2024

EXCEPTIONAL CARE

01/11/2024

Good

11/15/2023

All treatments seem to be working well.

11/06/2023

Extremely satisfied with Dr. Nazha's careful listening to my concerns, providing treatment options, patiently listening to my wife's concerns and offering his valuable advice. I am very impressed by his mannerism and would definitely recommend him.

10/25/2023

Very good

10/19/2023

Emory has the best team there is.

09/22/2023

Good experience

09/14/2023

Emory staff and Dr Nazha"s group are outstanding communicators The relief they provide by their quick response to questions and concerns is in itself a healing medicine. Stress relief promotes healing.

09/06/2023

Everyone was great!

08/30/2023

My assigned Physician listens to me wanted to hear my story on my past treatments for my on illness. This was great.

08/27/2023

Listens to my questions, gives reasonable advice.

08/11/2023

Dr Nazha was very cocerned and thorough.

08/02/2023

I appreciate the care provided by the Doctor

05/19/2023

I would recommend my doctor to everyone

05/18/2023

Dr Nazha is always clear and concerned Good explanation of options.

05/10/2023

Dr Nazha is amazing. He came and talked to me in the lobby when he arrived before my appointment started. That impressed me and made me feel as more than just another patient

05/10/2023

Been great so far

04/05/2023

So far I've felt good about the care of my doctor and his dedication to my welfare.

02/17/2023

My Doctor was extremely informative and helpful

01/15/2023

We cannot say enough about the quality of the services we have had at Emory.

01/06/2023

Dr. Nazha was fantastic about informing about my scans and blood work. Questions were answered before I asked them

10/28/2022

Dr. Bassel Lazha was passionate and had a caring mindset.

10/26/2022

Great

08/31/2022

Very nice p

08/21/2022

Oh. I found him to be very cold. Showed no signs of empathy

07/02/2022

We appreciate the the confidence, calm, and hope that Dr. Nazha provided us.